drugset / Trial / NCT02182245

Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

NCT02182245

Phase 1 Completed 22 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel

Timeline

Start
2005-10-01
Primary completion
2007-01-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule Oral
Background Carboplatin Small molecule
Background Paclitaxel Small molecule